Johnson & Johnson's epilepsy med Topamax won't go off patent in September as scheduled because the FDA has extended market exclusivity for one year based on a new pediatric indication for the med. Report [1]
Johnson & Johnson's epilepsy med Topamax won't go off patent in September as scheduled because the FDA has extended market exclusivity for one year based on a new pediatric indication for the med. Report [1]
Links:
[1] http://www.forbes.com/feeds/ap/2008/07/24/ap5252557.html